S
Sacha I. Rothschild
Researcher at University Hospital of Basel
Publications - 137
Citations - 4270
Sacha I. Rothschild is an academic researcher from University Hospital of Basel. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 27, co-authored 116 publications receiving 2900 citations. Previous affiliations of Sacha I. Rothschild include University of Basel & University of Bern.
Papers
More filters
Journal ArticleDOI
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
Julien Mazieres,Alexander Drilon,Amélie Lusque,Laurent Mhanna,Alexis B. Cortot,Laura Mezquita,A. Thai,C. Mascaux,Sébastien Couraud,Remi Veillon,M. van den Heuvel,Joel W. Neal,Nir Peled,Martin Früh,Terry L. Ng,Valérie Gounant,Sanjay Popat,Joachim Diebold,Joshua K. Sabari,Viola W. Zhu,Sacha I. Rothschild,Paolo Bironzo,Alex Martinez-Marti,Alessandra Curioni-Fontecedro,Rafael Rosell,Mickaël Lattuca-Truc,Marcel Wiesweg,Benjamin Besse,Benjamin Solomon,Fabrice Barlesi,R.D. Schouten,Heather A. Wakelee,D.R. Camidge,Gérard Zalcman,Silvia Novello,S-H.I. Ou,Julie Milia,Oliver Gautschi +37 more
TL;DR: In certain subgroups, PFS was positively associated with PD-L1 expression (KRAS, EGFR) and with smoking status (BRAF, HER2) and the lack of response in the ALK group was notable.
Journal ArticleDOI
Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort
Julien Mazieres,Gérard Zalcman,L. Crinò,Pamela Biondani,Fabrice Barlesi,Thomas Filleron,Anne-Marie C. Dingemans,Hervé Lena,Isabelle Monnet,Sacha I. Rothschild,Federico Cappuzzo,Benjamin Besse,Luc Thiberville,Damien Rouviere,Rafal Dziadziuszko,Egbert F. Smit,Jürgen Wolf,Christian Spirig,Nicolas Pécuchet,Frauke Leenders,Johannes M. Heuckmann,Joachim Diebold,Julie Milia,Roman K. Thomas,Oliver Gautschi +24 more
TL;DR: Crizotinib was highly active at treating lung cancer in patients with a ROS1 rearrangement, suggesting that patients with lung adenocarcinomas should be tested for ROS1.
Journal ArticleDOI
Targeting RET in patients with RET-rearranged lung cancers: Results from the global, multicenter RET registry
Oliver Gautschi,Julie Milia,Thomas Filleron,Juergen Wolf,David P. Carbone,Dwight H. Owen,R. Camidge,Vignhesh Narayanan,Robert C. Doebele,Benjamin Besse,Jordi Remon-Masip,Pasi A. Jänne,Mark M. Awad,Nir Peled,Chul Cho Byoung,Daniel D. Karp,Michael Van Den Heuvel,Heather A. Wakelee,Joel W. Neal,Tony Mok,James Chih-Hsin Yang,Sai-Hong Ignatius Ou,Georg Pall,Patrizia Froesch,Gérard Zalcman,David R. Gandara,Jonathan W. Riess,Vamsidhar Velcheti,Kristin Zeidler,Joachim Diebold,Martin Früh,Sebastian Michels,Isabelle Monnet,Sanjay Popat,Rafael Rosell,Niki Karachaliou,Sacha I. Rothschild,Jin-Yuan Shih,Arne Warth,Thomas Muley,Florian Cabillic,Julien Mazieres,Alexander Drilon +42 more
TL;DR: The results of an international registry of patients with RET-rearranged NSCLCs, providing the largest data set, to the authors' knowledge, on outcomes of RET-directed therapy thus far, are presented.
Journal ArticleDOI
Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study.
Viktor H. Koelzer,Sacha I. Rothschild,Deborah Zihler,Andreas Wicki,Berenika Willi,Niels Willi,Michèle Voegeli,Gieri Cathomas,Alfred Zippelius,Kirsten D. Mertz +9 more
TL;DR: A comprehensive analysis of systemic irAE pathology based on the autopsy of a 35-year-old female patient with metastatic melanoma treated first with ipilimumab and then nivolumab finds a clinically unapparent but histologically striking systemic inflammation involving the heart, central nervous system, liver and bone marrow.
Journal ArticleDOI
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort
Oliver Gautschi,Julie Milia,Bastien Cabarrou,Marie-Virginia Bluthgen,Benjamin Besse,Egbert F. Smit,Juergen Wolf,Solange Peters,Martin Früh,Dieter Koeberle,Youssouf Oulkhouir,Martin Schuler,Alessandra Curioni-Fontecedro,Benjamin Huret,Mallorie Kerjouan,Sebastian Michels,Georg Pall,Sacha I. Rothschild,Gerald Schmid-Bindert,Matthias Scheffler,Remi Veillon,Luciano Wannesson,Joachim Diebold,Gérard Zalcman,Thomas Filleron,Julien Mazieres +25 more
TL;DR: These results confirm the activity of targeted therapy in patients with BRAF-mutant lung adenocarcinoma and further trials are warranted to study combination therapies and drug resistance mechanisms.